• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Oncology

Analysis of early-onset colorectal cancer incidence by age, subsite, and histologic subtype

byThomas SuandDeepti Shroff
January 28, 2021
in Oncology
Reading Time: 3 mins read
Sunitinib showed no change in overall survival for metastatic prostate cancer
Share on FacebookShare on Twitter

1. While carcinoids contribute more heavily to the total incidence of early-onset colorectal cancer than they did in 2000, adenocarcinomas have also become more prevalent in nearly all subgroups.

2. Younger patients are experiencing the greatest growth in incidence rate, highlighting the necessity of risk-stratification and early diagnostic testing.

Evidence Rating Level: 2 (Good)

Study Rundown: Colorectal cancer is the third leading cause of cancer death in the United States, with a lifetime risk of roughly 1 in 25 in both men and women. While the overall incidence of colorectal cancer has been decreasing for the past several decades according to SEER data, detected cases of early-onset colorectal cancer (EOCRC) have instead been steadily rising in number. Previous analyses have generally focused on overall CRC incidence with little emphasis on specific histological subtypes. However, identification of the fastest-growing cancer types and the highest risk groups is critical in order to better inform the potential modification of controversial screening guidelines. This retrospective study found that, while the two youngest age groups still had the lowest absolute incidence rates, they also experienced the steepest increase in rectal adenocarcinoma. While adenocarcinoma comprised the bulk of CRC cases throughout the study, these changes were generally overshadowed by the increase in carcinoid tumors across all age groups, resulting in an increased contribution to the total number of CRC cases over time. It is unclear whether these trends can be attributed to a true increase in tumors due to lifestyle factors or simply to advances in endoscopic detection, but the results of this study reflected the importance of maximizing screening efforts in older and higher-risk individuals. Further, the finding that adenocarcinomas were found to be increasing in the most early-onset subgroups had implications for the adjustment of the average-risk screening age from 50 to 45 years.

Click here to read the study, published today in Annals of Internal Medicine

Click here to read an accompanying editorial, published today in Annals of Internal Medicine

RELATED REPORTS

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

2 Minute Medicine Rewind June 29, 2026

2 Minute Medicine Rewind May 25, 2026

Relevant Reading: Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010

In-Depth [retrospective cohort]: This study utilized SEER 18 data from 2000 to 2016 to examine all CRC cases in patients between the ages of 20 and 54 years. To minimize the effects of short-term fluctuations in incidence rate, rate comparisons were generated using a three-year average for the study period flanks (2000-2002 and 2014-2016). While the two younger age groups had manifold fewer cases overall compared to the two older age groups (16131 versus 107012 cases), they also had the greatest change in adenocarcinoma incidence. Specifically, there were increases of 39% in rectal-only cases in both patients aged 20-29 years (0.33 to 0.46 per 100,000) and those aged 30-39 years (1.92 to 2.66 per 100,000); colon-only cases in those aged 30-39 years also increased by 20% (3.30 to 3.97 per 100,000). Smaller increases in the range of 10-16% were also observed in the 40-49 and 50-54 age groups. The only categories that did not display a statistically significant gain in adenocarcinoma incidence over time were colon-only cases in the youngest age group and both colon-only and colorectal cases in the oldest. On the other hand, rectal carcinoid tumors increased significantly in all age groups, with the steepest changes occurring in those aged 20-29 (113% [0.08 to 0.17 per 100,000]) and those aged 50-54 (+159% [2.36 to 6.10 per 100,000]).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adenocarcinomacolorectal cancer
Previous Post

Self-obtained vaginal swabs for Neisseria gonorrhoeae and Chlamydia trachomatis found to be non-inferior to provider administrated sampling

Next Post

#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands

RelatedReports

Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Male sex and hispanic ethnicity are associated with increased risk of early-onset colorectal cancer

June 29, 2026
Weekly Rewinds

2 Minute Medicine Rewind June 29, 2026

June 29, 2026
Wide international variation in survival for periviable neonates
Weekly Rewinds

2 Minute Medicine Rewind May 25, 2026

May 25, 2026
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

The incidence of early-onset metastatic adenocarcinoma may be higher among patients with multiple metastatic sites and peritoneal involvement

April 30, 2026
Next Post
#VisualAbstract: Margetuximab improves progression-free survival in patients with ERBB2⁺ advanced breast cancer compared to trastuzumab

#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis

Machine learning-based PRAISE score may aid in the prediction of adverse events following an acute coronary syndrome

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.